Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 25,190 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PRE Clear all
Terminated Phase 1 Interventional

Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection

NCT01249443
View directory record Official record
Conditions
HIV Infection, Recurrent Anal Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Anal Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
vorinostat, diagnostic laboratory biomarker analysis, pharmacological study, carboplatin, paclitaxel
Drug · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Nov 15, 2026, 8:45 AM EST
Active, not recruiting Not applicable Interventional

The Effects of Virtual Reality Greenspace on Stress Among Adults With Mobility Impairments

NCT06682143
View directory record Official record
Conditions
Mobility Impairments
Interventions
Virtual Reality (VR), Control
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Nov 15, 2026, 8:45 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Wellness Intervention for Nurses Post Traumatic Growth and Selfcare

NCT06674876
View directory record Official record
Conditions
Trauma, Psychological, Moral Injury, Compassion Fatigue
Interventions
Blog writing
Behavioral
Lead sponsor
Purdue University
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Nov 15, 2026, 8:45 AM EST
Withdrawn No phase listed Observational Accepts healthy volunteers

Inferior Vena Cava (IVC) Diameters Before & After Interscalene Block

NCT03989076
View directory record Official record
Conditions
IVC - Inferior Vena Cava Abnormality
Interventions
Interscalene Brachial Plexus Block
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Nov 15, 2026, 8:45 AM EST
Active, not recruiting Not applicable Interventional

Addressing Financial and Social Needs Among Patients With Cancer

NCT06430840
View directory record Official record
Conditions
Cancer, Financial Hardship
Interventions
CostCOM (Cost Communication, Financial navigation and counseling), Provision of local and national resources to address financial and social needs, Financial Education, Usual care, Screening for financial and social needs
Behavioral · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Costa Mesa, California • Fountain Valley, California • Irvine, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Nov 15, 2026, 8:45 AM EST
Not listed No phase listed Observational Accepts healthy volunteers

White Light Scanning to Aid Body Contouring: A Pilot Project

NCT01093950
View directory record Official record
Conditions
Lipodystrophy, Body Dysmorphic Disorders
Interventions
Not listed
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2020
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Nov 15, 2026, 8:45 AM EST
Completed Phase 2 Interventional Results available

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

NCT00899847
View directory record Official record
Conditions
Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma, Blood and Marrow Transplant (BMT)
Interventions
Autologous peripheral blood stem cells (auto-PBSC) transplantation, Allogeneic peripheral blood stem cells (allo-PBSC) transplantation, Filgrastim, Cyclophosphamide, Melphalan, Cyclosporine, Total lymphoid irradiation, Rabbit anti-thymocyte globulin, Mycophenolate Mofetil 250mg, Solumedrol, Diphenhydramine, Acetaminophen, Hydrocortisone
Procedure · Drug · Radiation + 1 more
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Nov 15, 2026, 8:45 AM EST
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Nov 15, 2026, 8:45 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD)

NCT04901455
View directory record Official record
Conditions
COPD
Interventions
LAIV
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 15, 2026, 8:45 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Behavior, Executive Function, Neurotransmitter Function and Genomic Expression Kuvan Nonresponders

NCT01274026
View directory record Official record
Conditions
Phenylketonuria, Behavior and Behavior Mechanisms, PAH Gene Expression
Interventions
sapropterin dihydrochloride
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
2 Years to 21 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Nov 15, 2026, 8:45 AM EST
Not listed Not applicable Interventional

Blood Glucose Stability and Variability on Two Diets

NCT01443143
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Portion-controlled diet, Usual Diet
Other · Dietary Supplement
Lead sponsor
Nutrisystem, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2011 · Synced Nov 15, 2026, 8:45 AM EST
Completed Not applicable Interventional Results available

Disrupt CAD III With the Shockwave Coronary IVL System

NCT03595176
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Infarction
Interventions
Lithotripsy
Device
Lead sponsor
Shockwave Medical, Inc.
Industry
Eligibility
Not listed
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
39
States / cities
Scottsdale, Arizona • La Jolla, California • Orange, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Nov 15, 2026, 8:45 AM EST
Terminated Phase 2 Interventional

Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation

NCT02338050
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
Moxetumomab Pasudotox
Biological
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
6 Months to 24 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2015 · Synced Nov 15, 2026, 8:45 AM EST
Not listed Phase 4 Interventional Accepts healthy volunteers

A Prospective Pilot Study of a Non-Narcotic Post-Operative Course After Colectomy

NCT05200806
View directory record Official record
Conditions
Analgesia, Post-Operative Pain, Breakthrough Pain, Colectomy
Interventions
Non-Narcotic ERAS Post-Operative Pain Management
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Nov 15, 2026, 8:45 AM EST
Enrolling by invitation Not applicable Interventional

Impella ECP Study (ECP Study) and Impella ECP Continued Access Protocol

NCT05334784
View directory record Official record
Conditions
High-Risk Percutaneous Coronary Intervention
Interventions
Impella ECP
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
856 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Nov 15, 2026, 8:45 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Strength Training Induced Alterations in Markers of Immune Function

NCT01450852
View directory record Official record
Conditions
Inflammation
Interventions
Strength Training
Behavioral
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 30 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Nov 15, 2026, 8:45 AM EST
Completed Phase 2 Interventional Results available

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

NCT03856047
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0174-0833, Placebo (NNC0174-0833), Liraglutide 3.0 mg, Placebo (Liraglutide 3.0 mg)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
22
States / cities
Anaheim, California • Spring Valley, California • Crystal River, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Nov 15, 2026, 8:45 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Use of Platelet Rich Fibrin in Pulpal and Periodontal Regeneration in Mature Teeth

NCT02477358
View directory record Official record
Conditions
Pulpal Necrosis
Interventions
Left Tooth Platelet Rich Fibrin; Right Tooth Implant Alone, Right Tooth Platelet Rich Fibrin; Left Tooth Implant Alone
Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Nov 15, 2026, 8:45 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers

NCT02236026
View directory record Official record
Conditions
Healthy
Interventions
Supratherapuetic dose of Nestorone, Placebo, Moxifloxacin
Drug
Lead sponsor
Population Council
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Nov 15, 2026, 8:45 AM EST
Completed Phase 3 Interventional Results available

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures

NCT02548143
View directory record Official record
Conditions
Hemophilia
Interventions
Coagulation Factor VIIa (Recombinant)
Biological
Lead sponsor
Laboratoire français de Fractionnement et de Biotechnologies
Industry
Eligibility
6 Months to 75 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2022 · Synced Nov 15, 2026, 8:45 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

NCT03978143
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F, Treatment G, Treatment H
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Nov 15, 2026, 8:45 AM EST
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Optimizing PTCy Dose and Timing

NCT03983850
View directory record Official record
Conditions
Graft Versus Host Disease, Hematologic Neoplasms
Interventions
Busulfan, Fludarabine, Cyclophosphamide, Mycophenolate Mofetil, Sirolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Nov 15, 2026, 8:45 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk

NCT05576350
View directory record Official record
Conditions
Risk Behavior, Alcohol Use Disorder, HIV Infections
Interventions
Smartphone Based Alcohol Monitoring (SAM), Tracking and Reducing Alcohol Consumption (TRAC), TRAC-ER
Behavioral
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 35 Years
Enrollment
405 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Nov 15, 2026, 8:45 AM EST
Withdrawn Phase 2 Interventional

Naloxegol for Opioid-Related Gastroparesis

NCT03036891
View directory record Official record
Conditions
Gastroparesis, Opioid Use
Interventions
Naloxegol 25 MG Oral Tablet [Movantik], Placebo Oral Tablet
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 84 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Nov 15, 2026, 8:45 AM EST